LeonaBio grants 28,000 stock options to director

LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation.

Rhea-AI Filing Summary

LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation. The award covers 28,000 stock options for common stock with an exercise price of $8.35 per share, expiring on June 22, 2036.

The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Following this grant, she holds 28,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider Kosacz Barbara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Key Figures

Options granted: 28,000 options Exercise price: $8.35 per share Expiration date: June 22, 2036 +3 more

6 metrics

Options granted 28,000 options Stock option grant to director Barbara Kosacz

Exercise price $8.35 per share Stock option strike price for LeonaBio common stock

Expiration date June 22, 2036 Option term end date

Vesting date trigger June 23, 2027 Latest vesting date, subject to earlier stockholder meeting condition

Alternative vesting trigger Day before next annual meeting after June 22, 2026 Earlier vesting condition

Derivative holdings after grant 28,000 derivative securities Total options held directly following transaction

Key Terms

Stock Option (Right to Buy), Outside Director Compensation Policy, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Outside Director Compensation Policy financial

"The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy."

vesting financial

"The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeonaBio (LONA) report for Barbara Kosacz?

LeonaBio reported a stock option grant to director Barbara Kosacz. She received 28,000 options for common stock at a $8.35 exercise price, expiring June 22, 2036, as part of the company’s outside director compensation policy.

How many LeonaBio (LONA) stock options did Barbara Kosacz receive and at what price?

Barbara Kosacz received 28,000 LeonaBio stock options. Each option allows her to buy one share of common stock at an exercise price of $8.35 per share, providing potential future equity upside if the market price exceeds that level.

When do Barbara Kosacz’s LeonaBio (LONA) stock options vest?

The options vest based on the earlier of two dates. Vesting occurs on June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, aligning her compensation with board service timing.

When do the newly granted LeonaBio (LONA) stock options expire?

The granted stock options expire on June 22, 2036. This long-dated expiration gives Barbara Kosacz a multi-year window after vesting to decide whether to exercise the options, depending on LeonaBio’s share price performance and her personal decisions.

Is the LeonaBio (LONA) option grant to Barbara Kosacz a market purchase or compensation?

The transaction is a compensation-related grant, not a market purchase. The Form 4 shows transaction code A, indicating a grant or award under LeonaBio’s Outside Director Compensation Policy rather than an open-market buy or sell of existing shares.

How many derivative securities does Barbara Kosacz hold in LeonaBio (LONA) after this grant?

After the grant, Barbara Kosacz holds 28,000 derivative securities. These represent stock options for LeonaBio common stock, all held directly, and their future value depends on vesting, the $8.35 exercise price, and the company’s share price over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kosacz Barbara

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	06/23/2026		A		28,000		(1)	06/22/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

	/s/ Mark Worthington, Attorney in fact for Barbara Kosacz	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)